[#item_full_content] MMJ International Holdings, an FDA IND-stage pharmaceutical cannabinoid developer, is a plaintiff in landmark litigation before the U.S. District Court for the District of Columbia challenging CMS’s Substance Access Beneficiary Engagement Incentive – a program that, for the first time, introduces non-FDA-approved cannabinoid products into the Medicare delivery system without notice, public comment, or safety review. 
Read More
Federal Judge to Decide Whether Medicare Can Distribute Hemp-Marijuana Cannabinoids Without FDA Approval
ByPot Shop News
April 25, 2026